Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006363 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
A Phase 3 study of Adult Acute Minimally Differentiated Myeloid Leukemia (M0) and Adult Acute Monocytic Leukemia (M5b), sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
- 1
- Study location
NCT00006363 is a Phase 3 study of Adult Acute Minimally Differentiated Myeloid Leukemia (M0) and Adult Acute Monocytic Leukemia (M5b) that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 720 participants, above the 136-participant average among 8 other Adult Acute Minimally Differentiated Myeloid Leukemia (M0) trials with a reported enrollment target (429% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00006363, a Phase 3 study of Adult Acute Minimally Differentiated Myeloid Leukemia (M0) and Adult Acute Monocytic Leukemia (M5b), has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
- 1
- Study location
Study Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. This randomized phase III trial is studying giving combination chemotherapy together with PSC 833 followed by a peripheral stem cell transplant with or without interleukin-2 to see how well it works compared to combination chemotherapy alone followed by a peripheral stem cell transplant with or without interleukin-2 in treating patients with acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG daunorubicin hydrochloride
- DRUG valspodar
Study Locations (1)
Illinois
- Cancer and Leukemia Group B - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2000-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006363
The ClinicalTrials.gov registry entry for NCT00006363 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 136-participant average among 8 other Adult Acute Minimally Differentiated Myeloid Leukemia (M0) trials with a reported enrollment target (429% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Adult Acute Minimally Differentiated Myeloid Leukemia (M0) appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT00006363 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00006363 about?
NCT00006363 is a clinical study titled "Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia". Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs. Combining chemotherapy with peripheral stem cell transplantation may allow the doct...
What is the current status of trial NCT00006363?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2000-11.
What conditions does trial NCT00006363 study?
This clinical trial studies the following conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Megakaryoblastic Leukemia (M7).
What interventions are being tested in trial NCT00006363?
The interventions under investigation include: etoposide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), daunorubicin hydrochloride (DRUG), valspodar (DRUG).
Who is sponsoring clinical trial NCT00006363?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006363 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
COMPLETED · Phase 3
-
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
COMPLETED · Phase 1
-
XK469R in Treating Patients With Refractory Hematologic Cancer
COMPLETED · Phase 1
-
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
COMPLETED · Phase 1
-
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
COMPLETED · Phase 1
-
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
COMPLETED · Phase 2
Explore more on PlainTrial
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
All registered trials for this condition
Adult Acute Monocytic Leukemia (M5b)
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.